Tirupakuzhi Vijayaraghavan, Bharath Kumar, Bishnu, Saptarshi, Baruch, Joaquin, Citarella, Barbara Wanjiru, Kartsonaki, Christiana, Meeyai, Aronrag, Mohamed, Zubair, Ohshimo, Shinichiro, Lefèvre, Benjamin, Al-Fares, Abdulrahman et al (show 6 more authors)
(2023)
Liver injury in hospitalized patients with COVID-19: An International observational cohort study.
PloS one, 18 (9).
e0277859-e0277859.
|
PDF
Liver injury in hospitalized patients with COVID-19 An International observational cohort study.pdf - Open Access published version Download (469kB) | Preview |
Abstract
<h4>Background</h4>Using a large dataset, we evaluated prevalence and severity of alterations in liver enzymes in COVID-19 and association with patient-centred outcomes.<h4>Methods</h4>We included hospitalized patients with confirmed or suspected SARS-CoV-2 infection from the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) database. Key exposure was baseline liver enzymes (AST, ALT, bilirubin). Patients were assigned Liver Injury Classification score based on 3 components of enzymes at admission: Normal; Stage I) Liver injury: any component between 1-3x upper limit of normal (ULN); Stage II) Severe liver injury: any component ≥3x ULN. Outcomes were hospital mortality, utilization of selected resources, complications, and durations of hospital and ICU stay. Analyses used logistic regression with associations expressed as adjusted odds ratios (OR) with 95% confidence intervals (CI).<h4>Results</h4>Of 17,531 included patients, 46.2% (8099) and 8.2% (1430) of patients had stage 1 and 2 liver injury respectively. Compared to normal, stages 1 and 2 were associated with higher odds of mortality (OR 1.53 [1.37-1.71]; OR 2.50 [2.10-2.96]), ICU admission (OR 1.63 [1.48-1.79]; OR 1.90 [1.62-2.23]), and invasive mechanical ventilation (OR 1.43 [1.27-1.70]; OR 1.95 (1.55-2.45). Stages 1 and 2 were also associated with higher odds of developing sepsis (OR 1.38 [1.27-1.50]; OR 1.46 [1.25-1.70]), acute kidney injury (OR 1.13 [1.00-1.27]; OR 1.59 [1.32-1.91]), and acute respiratory distress syndrome (OR 1.38 [1.22-1.55]; OR 1.80 [1.49-2.17]).<h4>Conclusions</h4>Liver enzyme abnormalities are common among COVID-19 patients and associated with worse outcomes.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | ISARIC Clinical Characterisation Group |
| Divisions: | Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Infection, Veterinary and Ecological Sciences |
| Depositing User: | Symplectic Admin |
| Date Deposited: | 16 Nov 2023 15:41 |
| Last Modified: | 16 Nov 2023 15:43 |
| DOI: | 10.1371/journal.pone.0277859 |
| Related URLs: | |
| URI: | https://livrepository.liverpool.ac.uk/id/eprint/3176845 |
Dimensions
Dimensions
